Abstract: The present disclosure relates to novel methods of discriminating and/or detecting mis-matched polynucleotide populations in a sample by determining the ratios of mismatched polynucleotide species after specific enzymatic digestion treatment. Aspects of this disclosure includes obtaining, enhancing and/or determining the amount of one DNA or RNA species versus another in a given sample following enzyme digestion treatment; determining the relative abundance of the species contained in the sample based on the changes in the relative ratios following enzymatic treatment.

Abstract: A method is disclosed for highly efficient DNA sequence alterations. The method is useful for editing chromosomes, to engineer cellular markers through insertion of genes, or to create epigenetic changes by using cas9-enzyme fusions where the enzymes can be DNA epigenetic modifying enzymes or chromatin modifying enzymes, etc. The technology also differs from all previously known technologies in that the CRISPR/Cas system can function in ways that are “clean”, i.e. they have not been in contact with any virus, or are carried DNA molecules that can insert into the chromosome in unintended locations.

Abstract: The present disclosure relates to methods and compositions comprising naturally occurring light absorbing molecules for preventing damages from light exposure. Specific embodiments of this disclosure include fluorescent proteins from Brachiostoma lanceolatum.

Abstract: The present disclosure relates to novel methods of discriminating and/or detecting mis-matched polynucleotide populations in a sample by determining the ratios of mismatched polynucleotide species after specific enzymatic digestion treatment. Aspects of this disclosure includes obtaining, enhancing and/or determining the amount of one DNA or RNA species versus another in a given sample following enzyme digestion treatment; determining the relative abundance of the species contained in the sample based on the changes in the relative ratios following enzymatic treatment.

Abstract: The present disclosure relates generally to novel methods and compositions for using engineered reprogramming factor(s) for the creation of induced pluripotent stem cells (iPSCs) through a kinetically controlled process. Specifically, this disclosure relates to establishing combinations of reprogramming factors, including fusions between conventional reprogramming factors with transactivation domains, optimized for reprogramming various types of cells. More specifically, the exemplary methods disclosed herein can be used for creating induced pluripotent stem cells from various mammalian cell types, including human fibroblasts. Exemplary methods of feeder-free derivation of human induced pluripotent stem cells using synthetic messenger RNA are also disclosed.

Abstract: The present disclosure provides isolated nucleic acid sequences encoding a monomeric green/yellow fluorescent proteins, and fragments and derivatives thereof. Also provided is a method for engineering the nucleic acid sequence, a vector comprising the nucleic acid sequence, a host cell comprising the vector, and use of the vector in a method for expressing the nucleic acid sequence. The present invention further provides an isolated nucleic acid, or mimetic or complement thereof, that hybridizes under stringent conditions to the nucleic acid sequence. Additionally, the present invention provides a monomeric green/yellow fluorescent protein encoded by the nucleic acid sequence, as well as derivatives, fragments, and homologues thereof. Also provided is an antibody that specifically binds to the green/yellow fluorescent protein.

Abstract: The present disclosure provides isolated nucleic acid sequences encoding a monomeric green/yellow fluorescent proteins, and fragments and derivatives thereof. Also provided is a method for engineering the nucleic acid sequence, a vector comprising the nucleic acid sequence, a host cell comprising the vector, and use of the vector in a method for expressing the nucleic acid sequence. The present invention further provides an isolated nucleic acid, or mimetic or complement thereof, that hybridizes under stringent conditions to the nucleic acid sequence. Additionally, the present invention provides a monomeric green/yellow fluorescent protein encoded by the nucleic acid sequence, as well as derivatives, fragments, and homologues thereof. Also provided is an antibody that specifically binds to the green/yellow fluorescent protein.

Abstract: The present disclosure relates generally to novel methods and compositions for using engineered reprogramming factor(s) for the creation of induced pluripotent stem cells (iPSCs) through a kinetically controlled process. Specifically, this disclosure relates to establishing combinations of reprogramming factors, including fusions between conventional reprogramming factors with transactivation domains, optimized for reprogramming various types of cells. More specifically, the exemplary methods disclosed herein can be used for creating induced pluripotent stem cells from various mammalian cell types, including human fibroblasts. Exemplary methods of feeder-free derivation of human induced pluripotent stem cells using synthetic messenger RNA are also disclosed.

Abstract: A novel method of inducing neural progenitor cells, oligodendrocyte progenitor cells, oligodendrocytes from human iPSCs at an unprecedented efficiency and functionality. The core of the invention is the use of experimentally discovered transcription factors at multiple critical differentiation decision points along a pluripotent to ectoderm, neural ectoderm to NPCs to OPCs to oligodendrocytes pathway in a previously unknown manner.

Abstract: The present disclosure relates generally to novel methods and compositions for using engineered reprogramming factor(s) for the creation of induced pluripotent stem cells (iPSCs) through a kinetically controlled process. Specifically, this disclosure relates to establishing combinations of reprogramming factors, including fusions between conventional reprogramming factors with transactivation domains, optimized for reprogramming various types of cells. More specifically, the exemplary methods disclosed herein can be used for creating induced pluripotent stem cells from various mammalian cell types, including human fibroblasts. Exemplary methods of feeder-free derivation of human induced pluripotent stem cells using synthetic messenger RNA are also disclosed.

Abstract: The present disclosure relates generally to novel methods and compositions for using engineered reprogramming factor(s) for the creation of induced pluripotent stem cells (iPSCs) through a kinetically controlled process. Specifically, this disclosure relates to establishing combinations of reprogramming factors, including fusions between conventional reprogramming factors with transactivation domains, optimized for reprogramming various types of cells. More specifically, the exemplary methods disclosed herein can be used for creating induced pluripotent stem cells from various mammalian cell types, including human fibroblasts. Exemplary methods of feeder-free derivation of human induced pluripotent stem cells using synthetic messenger RNA are also disclosed.

Abstract: A novel method of inducing or producing pancreatic beta cells from human induced pluripotent stem cells at an unprecedented efficiency and functionality. The core of the invention is the use of experimentally discovered mRNAs at multiple critical differentiation decision points along a pluripotent to mesendoderm to endoderm to pancreatic endocrine cells to pancreatic beta cells pathway in a previously unknown manner.

Abstract: A novel method of inducing or producing hepatocytes from human induced pluripotent stem cells at an unprecedented efficiency and functionality. The core of the invention is the use of experimentally discovered mRNAs at multiple critical differentiation decision points along a pluripotent to mesendoderm to endoderm to hepatocytes pathway in a previously unknown manner.

Abstract: The present disclosure relates to methods and compositions comprising naturally occurring light absorbing molecules for preventing damages from light exposure. Specific embodiments of this disclosure include fluorescent proteins from Brachiostoma lanceolatum.

Abstract: The present disclosure relates to methods and compositions comprising naturally occurring light absorbing molecules for preventing damages from light exposure. Specific embodiments of this disclosure include fluorescent proteins from Brachiostoma lanceolatum.

Abstract: A multi-step method is disclosed for efficient selection of antibody or antibody fragments. In addition to the dramatically increased efficiency of finding antibodies against a given immunogen by the invented processes, the novel technology also differs from all previously known technologies in that the antibody or antibody fragments represent the most abundant antibodies induced by the immunogen, therefore having the highest potential of specificity and affinity. Utility of the invention can be found in virtually all areas that involve antibody or T cell receptor selection using any animal, against any immunogen.

Abstract: The present disclosure relates to methods and compositions comprising naturally occurring light absorbing molecules for preventing damages from light exposure. Specific embodiments of this disclosure include fluorescent proteins from Brachiostoma lanceolatum.

Abstract: The present disclosure relates to methods and compositions comprising naturally occurring light absorbing molecules for preventing damages from light exposure. Specific embodiments of this disclosure include fluorescent proteins from Brachiostoma lanceolatum.

Abstract: The present disclosure provides an isolated nucleic acid sequence encoding a monomeric photoconvertible fluorescent protein, and fragments and derivatives thereof. Also provided is a method for engineering the nucleic acid sequence, a vector comprising the nucleic acid sequence, a host cell comprising the vector, and use of the vector in a method for expressing the nucleic acid sequence. The present disclosure further provides an isolated nucleic acid, or mimetic or complement thereof, that hybridizes under stringent conditions to the nucleic acid sequence. Additionally, the present provides a monomeric photoconvertible fluorescent protein encoded by the nucleic acid sequence, as well as derivatives, fragments, and homologues thereof. Also provided is an antibody that specifically binds to the photoconvertible fluorescent protein.

Abstract: The present disclosure relates generally to novel methods and compositions for using engineered reprogramming factor(s) for the creation of induced pluripotent stem cells (iPSCs) through a kinetically controlled process. Specifically, this disclosure relates to establishing combinations of reprogramming factors, including fusions between conventional reprogramming factors with transactivation domains, optimized for reprogramming various types of cells. More specifically, the exemplary methods disclosed herein can be used for creating induced pluripotent stem cells from various mammalian cell types, including human fibroblasts. Exemplary methods of feeder-free derivation of human induced pluripotent stem cells using synthetic messenger RNA are also disclosed.